-
公开(公告)号:US20230364212A1
公开(公告)日:2023-11-16
申请号:US18170994
申请日:2023-02-17
Applicant: Think Therapeutics, Inc.
Inventor: David Kenneth GIFFORD , Brandon CARTER
CPC classification number: A61K39/00116 , A61K38/08 , A61K38/10 , A61K39/001152 , A61K39/001158 , C07K7/06 , C07K7/08 , A61P35/00 , A61K2039/86 , A61K48/00
Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.
-
公开(公告)号:US11672850B2
公开(公告)日:2023-06-13
申请号:US17729290
申请日:2022-04-26
Applicant: Think Therapeutics, Inc.
Inventor: David Kenneth Gifford , Brandon Carter
IPC: A61K39/00 , A61K38/00 , A61K38/10 , A61K38/08 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , C07K7/06 , C07K7/08 , A61P35/00 , A61K48/00
CPC classification number: A61K39/00116 , A61K38/08 , A61K38/10 , A61K39/001152 , A61K39/001158 , A61P35/00 , C07K7/06 , C07K7/08 , A61K48/00 , A61K2039/812 , A61K2039/82 , A61K2039/86
Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.
-
公开(公告)号:US20240075116A1
公开(公告)日:2024-03-07
申请号:US18183082
申请日:2023-03-13
Applicant: CureVac SE
Inventor: Mariola FOTIN-MLECZEK , Ingmar HOERR
CPC classification number: A61K39/0011 , A61K39/001103 , A61K39/001104 , A61K39/001106 , A61K39/001107 , A61K39/001109 , A61K39/001119 , A61K39/001122 , A61K39/001139 , A61K39/00114 , A61K39/00115 , A61K39/001151 , A61K39/001156 , A61K39/001157 , A61K39/001158 , A61K39/00116 , A61K39/001162 , A61K39/001166 , A61K39/001168 , A61K39/001182 , A61K39/001184 , A61K39/001186 , A61K39/001188 , A61K39/00119 , A61K39/001191 , A61K39/001193 , A61K39/001194 , A61K39/001195 , A61P35/00 , A61K2039/53
Abstract: The present invention relates to an RNA encoding a tumor antigen. In particular, the present invention relates to RNA suitable for treatment and/or prophylaxis of cancer and related diseases. The present invention concerns such RNA as well as compositions, vaccines and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions, vaccines or kits as disclosed herein for use in the treatment and/or prophylaxis of cancer and related diseases.
-
公开(公告)号:US12064475B2
公开(公告)日:2024-08-20
申请号:US18170994
申请日:2023-02-17
Applicant: Think Therapeutics, Inc.
Inventor: David Kenneth Gifford , Brandon Carter
IPC: A61K39/00 , A61K38/00 , A61K38/04 , A61K38/08 , A61K38/10 , A61P35/00 , C07K5/00 , C07K7/00 , C07K7/06 , C07K7/08 , C07K16/00 , C07K17/00 , A61K48/00
CPC classification number: A61K39/00116 , A61K38/08 , A61K38/10 , A61K39/001152 , A61K39/001158 , A61P35/00 , C07K7/06 , C07K7/08 , A61K2039/812 , A61K2039/82 , A61K2039/86 , A61K48/00
Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.
-
-
-